Design Therapeutics, Inc.
DSGN
$14.83
$0.443.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 13.97% | 7.11% | |||
| Gross Profit | -13.97% | -7.11% | |||
| SG&A Expenses | 8.67% | 12.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.54% | 8.46% | |||
| Operating Income | -12.54% | -8.46% | |||
| Income Before Tax | -14.34% | -10.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.34% | -10.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.34% | -10.25% | |||
| EBIT | -12.54% | -8.46% | |||
| EBITDA | -12.67% | -8.53% | |||
| EPS Basic | -12.37% | -5.40% | |||
| Normalized Basic EPS | -12.37% | -5.41% | |||
| EPS Diluted | -12.37% | -5.40% | |||
| Normalized Diluted EPS | -12.37% | -5.41% | |||
| Average Basic Shares Outstanding | 1.74% | 4.60% | |||
| Average Diluted Shares Outstanding | 1.74% | 4.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||